<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>412-PENTOXIFYLLINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PENTOXIFYLLINE" rxcui="8013">
<ATC code="C04AD03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>412-PENTOXIFYLLINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PENTOXIFYLLINE" rxcui="8013">
<ATC code="C04AD03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pentoxifylline and a week after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>412-PENTOXIFYLLINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PENTOXIFYLLINE" rxcui="8013">
<ATC code="C04AD03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose (competition at the level of the hepatic metabolism of the theophylline)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the pentoxifylline and after it is stopped.</COMMENT>
</INTERACTION>
</INTERACTIONS>
